Tirzepatide for managing overweight and obesity

Tirzepatide (Mounjaro, Eli Lilly) is indicated for 'weight management, including weight loss and weight maintenance, as an adjunct to a reduced-calorie diet and increased physical activity in adults with an initial Body Mass Index (BMI) of:

• ≥30 kg/m² (obesity) or

• ≥27 kg/m² to <30 kg/m² (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus)'.

The dosage schedule is available in the summary of product characteristics for tirzepatide.

The list prices of tirzepatide (4‑week supply of pre-filled pen devices for subcutaneous injection) are:

• £92.00 for 2.5 mg and 5 mg

• £107.00 for 7.5 mg and 10 mg

• £122.00 for 12.5 mg and 15 mg.